From drug discovery to biomarker-driven clinical trials in lymphoma
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
From drug discovery to biomarker-driven clinical trials in lymphoma
Authors
Keywords
-
Journal
Nature Reviews Clinical Oncology
Volume 9, Issue 11, Pages 643-653
Publisher
Springer Nature
Online
2012-09-11
DOI
10.1038/nrclinonc.2012.156
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity of single agent temsirolimus (CCI-779) in non-mantle cell non-Hodgkin lymphoma subtypes
- (2017) S. M. Smith et al. JOURNAL OF CLINICAL ONCOLOGY
- Crizotinib and Testing for ALK
- (2017) Alice T. Shaw et al. Journal of the National Comprehensive Cancer Network
- Predictive Biomarkers in Advance of a Companion Drug: Ahead of Their Time?
- (2017) Robin K. Kelley et al. Journal of the National Comprehensive Cancer Network
- IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma
- (2012) R. A. Cairns et al. BLOOD
- Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics
- (2012) D. R. Parkinson et al. CLINICAL CANCER RESEARCH
- Analytical Performance of a Real-time PCR-based Assay for V600 Mutations in the BRAF Gene, Used as the Companion Diagnostic Test for the Novel BRAF Inhibitor Vemurafenib in Metastatic Melanoma
- (2012) Harkanwal Halait et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Translating cancer 'omics' to improved outcomes
- (2012) E. A. Vucic et al. GENOME RESEARCH
- Adaptive Clinical Trials
- (2012) William J. Meurer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Microarray Gene Expression Analysis of Fixed Archival Tissue Permits Molecular Classification and Identification of Potential Therapeutic Targets in Diffuse Large B-Cell Lymphoma
- (2012) Kim Linton et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Prepping Omics for the Clinic
- (2012) R. S. Tuma JNCI-Journal of the National Cancer Institute
- New report sets guidelines for omics research
- (2012) Norra MacReady LANCET ONCOLOGY
- Oxford Nanopore announcement sets sequencing sector abuzz
- (2012) Michael Eisenstein NATURE BIOTECHNOLOGY
- The road to resistance: EGFR mutation and cetuximab
- (2012) Alberto Bardelli et al. NATURE MEDICINE
- Oncology trials—the elephant in the room
- (2012) Rebecca Kirk et al. Nature Reviews Clinical Oncology
- Brentuximab vedotin
- (2012) Anas Younes et al. NATURE REVIEWS DRUG DISCOVERY
- Immunohistochemical Detection of MYC-driven Diffuse Large B-Cell Lymphomas
- (2012) Michael J. Kluk et al. PLoS One
- Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27)
- (2012) M. T. McCabe et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
- (2012) J. G. Lohr et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- New paradigms in translational science research in cancer biomarkers
- (2012) Paul D. Wagner et al. Translational Research
- Cancer biomarkers, companion diagnostics and personalized oncology
- (2011) Jeffrey S Ross Biomarkers in Medicine
- Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma
- (2011) R. Kridel et al. BLOOD
- Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium
- (2011) G. Salles et al. BLOOD
- Cancer Biomarkers: Closer to Delivering on their Promise
- (2011) Lance A. Liotta et al. CANCER CELL
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- BCL2 Predicts Survival in Germinal Center B-cell-like Diffuse Large B-cell Lymphoma Treated with CHOP-like Therapy and Rituximab
- (2011) J. Iqbal et al. CLINICAL CANCER RESEARCH
- New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice
- (2011) J. W. Friedberg CLINICAL CANCER RESEARCH
- Erlotinib, gefitinib, or chemotherapy for EGFR mutation-positive lung cancer?
- (2011) Tetsuya Mitsudomi LANCET ONCOLOGY
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- Quantitative image analysis in the assessment of diffuse large B-cell lymphoma
- (2011) Devon S Chabot-Richards et al. MODERN PATHOLOGY
- Translational research: 4 ways to fix the clinical trial
- (2011) Heidi Ledford NATURE
- Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
- (2011) Ryan D. Morin et al. NATURE
- Analysis of the coding genome of diffuse large B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE GENETICS
- Cancer genomics: from discovery science to personalized medicine
- (2011) Lynda Chin et al. NATURE MEDICINE
- Adaptive clinical trials in oncology
- (2011) Donald A. Berry Nature Reviews Clinical Oncology
- Role of randomized phase III trials in an era of effective targeted therapies
- (2011) Manish R. Sharma et al. Nature Reviews Clinical Oncology
- Phase III and submission failures: 2007–2010
- (2011) John Arrowsmith NATURE REVIEWS DRUG DISCOVERY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Utility of mTOR Inhibition in Hematologic Malignancies
- (2011) A. Younes et al. ONCOLOGIST
- An Overview of the Optimal Planning, Design, and Conduct of Phase I Studies of New Therapeutics
- (2010) P. M. LoRusso et al. CLINICAL CANCER RESEARCH
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab
- (2010) Wendy De Roock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study
- (2010) Anjali Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Adaptive Clinical Trials: The Promise and the Caution
- (2010) Donald A. Berry JOURNAL OF CLINICAL ONCOLOGY
- A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
- (2010) T E Witzig et al. LEUKEMIA
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Gene-expression-based prognostic assays for breast cancer
- (2010) Chungyeul Kim et al. Nature Reviews Clinical Oncology
- Beyond chemotherapy: new agents for targeted treatment of lymphoma
- (2010) Anas Younes Nature Reviews Clinical Oncology
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
- (2010) Eunice L. Kwak et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pathway-Based Identification of Biomarkers for Targeted Therapeutics: Personalized Oncology with PI3K Pathway Inhibitors
- (2010) J. N. Andersen et al. Science Translational Medicine
- The clinicopathological analysis of 303 cases with malignant lymphoma classified according to the World Health Organization classification system in a single institute of Taiwan
- (2009) Wei-Liang Chen et al. ANNALS OF HEMATOLOGY
- Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
- (2009) J. W. Friedberg et al. BLOOD
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- (2009) Andres Forero-Torres et al. BRITISH JOURNAL OF HAEMATOLOGY
- I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy
- (2009) AD Barker et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma
- (2009) Ranjana Advani et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial
- (2009) Kathy S Albain et al. LANCET ONCOLOGY
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- A practical approach to the understanding and diagnosis of lymphoma: an assessment of the WHO classification based on immunoarchitecture and immuno-ontogenic principles
- (2009) Leonard Hwan Cheong Tan PATHOLOGY
- Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma
- (2009) A. Younes Hematology-American Society of Hematology Education Program
- Classification of Non-Hodgkin's Lymphoma
- (2008) David J. Good et al. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now